Business
Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update
Wa'el Hashad Wa'el Hashad, CEO, Longeveron Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successfulResults from the Phase 2a clinical trial (CLEAR MIND) evaluating
About this update from Longeveron Inc.
[{"type":"image","alt":"Longeveron","displaySize":"","headline":null,"caption":"Longeveron","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":56,"url":"https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.X2J.blw.0f9XkdGnRbwAQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTc4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/7020f3e4e4ad01a05af1150b74d0406a","width":300,"height":56}},"lazy":false},{"type":"text","content":"Wa'el Hashad","length":16,"tagName":"p"},{"type":"image","alt":"Wa'el Hashad, CEO, Longeveron","displaySize":"","headline":null,"caption":"Wa'el Hashad, CEO, Longeveron","credit":"GlobeNewswire Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":907,"height":1280,"url":"https://media.zenfs.com/en/globenewswire.com/985aaedca6d8fa1db5b45699cb234963"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hZLnIg4nVu41VQzOxrCMhg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTEzNTU7Y2Y9d2VicA--/https://media.zenfs.com/en/globenewswire.com/985aaedca6d8fa1db5b45699cb234963","width":907,"height":1280},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NHV_NdOUWrkCMC9duEKhdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTE4MTQ7aD0yNTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/985aaedca6d8fa1db5b45699cb234963","width":907,"height":1280}}},{"type":"list","items":[{"val":[{"type":"text","content":"Pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel in HLHS, a rare pediatric disease and orphan-designated indication, has reached approximately 95% enrollment and is expected to complete enrollment in the second quarter of 2025","length":245,"tagName":"p"}]},{"val":[{"type":"text","content":"Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated in 2026, if ELPIS II is successful","length":147,"tagName":"p"}]},{"val":[{"type":"text","content":"Results from the Phase 2a clinical trial (CLEAR MIND) evaluating laromestrocel as a potential treatment for Alzheimer’s disease were published in Nature Medicine","length":161,"tagName":"p"}]},{"val":[{"type":"text","content":"Positive FDA meeting regarding development pathway for laromestrocel in mild Alzheimer’s disease; single, pivotal Phase 2/3 adaptive design clinical trial to support potential BLA submission",...